News
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
Participant Experiences & “Cover Story”
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
California State Senate Takes Step To Dismantle Psychedelic Prohibition
Fifty years after the War on Drugs was officially declared and psychedelic substance prohibition began in contravention of evidence supporting therapeutic use, the California State Senate has taken the …
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
Lawsuit Filed Against the DEA and Attorney General to Compel Issuance of Licenses to Manufacture Marijuana for Clinical Trials and Potential FDA Approval
On the heels of United Nations’ Commission on Narcotic Drugs removal of medical marijuana from the list of most dangerous drugs, lawsuit demands processing and approval of licenses to support research …
Lawsuit Filed Against the DEA and Attorney General to Compel Issuance of Licenses to Manufacture Marijuana for Clinical Trials and Potential FDA Approval
On the heels of United Nations’ Commission on Narcotic Drugs removal of medical marijuana from the list of most dangerous drugs, lawsuit demands processing and approval of licenses to support research …
Boulder: Study Officially Completed
On February 24, 2017, investigators gathered for the formal closeout of our Phase 2 study of MDMA-assisted psychotherapy in 23 subjects with chronic PTSD in Boulder, Colorado, led by Principal Investigator …
Israel: Three Participants Complete 12-Month Follow-Up
On February 2 and February 7, 2017, the eighth and ninth of 10 participants completed their 12-month follow-up interviews in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. The seventh …